Angusta for induction of labor: BfArM reminds doctors of dosage recommendations and contraindications

News Healthcare & Pharma Guidance

Date: 27th Jun, 2025 Source: Federal Institute for Drugs and Medical Devices (BfArM) Country: Germany Original Source

Brief

On 23/06/2023, the "Federal Institute for Drugs and Medical Devices (BfArM)" issued an update regarding "Angusta for induction of labor: BfArM reminds doctors of dosage recommendations and contraindications". The BfArM emphasizes that Angusta should only be used in hospitals with continuous monitoring of fetus and uterus, and not during active labor or with regular and painful contractions.

This content is restricted.

Highlights content goes here...

This content is restricted.

Federal Institute for Drugs and Medical Devices (BfArM)

RADA.AI

Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?

Suggested

Angusta for induction of labor: BfArM reminds doctors of dosage recommendations and contraindications

Brief

Federal Institute for Drugs and Medical Devices (BfArM)

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.

Angusta for induction of labor: BfArM reminds doctors of dosage recommendations and contraindications

Brief

Federal Institute for Drugs and Medical Devices (BfArM)

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify OTP

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.